Reversible lymphomagenesis in conditionally c-MYC expressing mice

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Deregulation of the MYC oncogene is a known driver of tumor development.
• The precise mechanisms by which MYC contributes to tumorigenesis are not fully understood.

Purpose of the Study:

• To establish a conditional transgenic mouse model for studying c-MYC-induced lymphoid tumors.
• To investigate the mechanisms of tumor regression and genomic instability associated with c-MYC overexpression.

Main Methods:

• Conditional c-MYC expression in lymphoid cells using a tetracycline-regulated system.
• Tumorigenesis and regression studies upon MYC inactivation with doxycycline.
• GFP-labeled tumor cell transplantation to track neoplastic cell fate.
• Comparative Genomic Hybridization (CGH) and Fluorescence In Situ Hybridization (FISH) for genomic analysis.

Main Results:

• Continuous c-MYC expression led to invasive T- or B-cell lymphomas within 4 months.
• Doxycycline treatment resulted in tumor regression, confirming c-MYC dependence.
• Tumor elimination involved both apoptosis and cellular differentiation.
• c-MYC overexpression induced genomic instability, notably trisomy of chromosome 15 in T-cell lymphomas.

Conclusions:

• Conditional c-MYC expression is sufficient to induce lymphoid tumors in mice.
• MYC-driven lymphomas are dependent on c-MYC for maintenance and can regress upon its inactivation.
• Tumor regression mechanisms include apoptosis and differentiation.
• c-MYC overexpression promotes genomic instability, potentially contributing to tumor progression.